Captrust Financial Advisors acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,130 shares of the biotechnology company’s stock, valued at approximately $925,000.
Several other large investors also recently modified their holdings of UTHR. State of Wisconsin Investment Board acquired a new stake in United Therapeutics Corporation during the second quarter worth about $5,256,000. Comerica Bank increased its stake in United Therapeutics Corporation by 1.3% during the second quarter. Comerica Bank now owns 35,249 shares of the biotechnology company’s stock worth $4,635,000 after acquiring an additional 458 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of United Therapeutics Corporation by 1.8% in the first quarter. JPMorgan Chase & Co. now owns 122,497 shares of the biotechnology company’s stock valued at $16,583,000 after buying an additional 2,223 shares in the last quarter. Clarity Capital KCPS Ltd. acquired a new stake in shares of United Therapeutics Corporation in the first quarter valued at about $230,000. Finally, River & Mercantile Asset Management LLP acquired a new stake in shares of United Therapeutics Corporation in the second quarter valued at about $908,000.
Shares of United Therapeutics Corporation (UTHR) traded down 1.40% during mid-day trading on Thursday, hitting $115.92. The stock had a trading volume of 90,440 shares. United Therapeutics Corporation has a 12-month low of $110.90 and a 12-month high of $169.89. The stock’s 50-day moving average price is $128.37 and its 200-day moving average price is $129.08. The stock has a market capitalization of $5.04 billion, a price-to-earnings ratio of 13.44 and a beta of 1.52.
United Therapeutics Corporation (NASDAQ:UTHR) last released its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.61 by ($4.86). The company had revenue of $444.60 million during the quarter, compared to analysts’ expectations of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.42 earnings per share. On average, equities analysts anticipate that United Therapeutics Corporation will post $10.09 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://ledgergazette.com/2017/09/21/captrust-financial-advisors-buys-shares-of-7130-united-therapeutics-corporation-uthr.html.
A number of research firms have recently issued reports on UTHR. BidaskClub lowered United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. ValuEngine downgraded United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Finally, Jefferies Group LLC reissued a “sell” rating and issued a $105.00 price target on shares of United Therapeutics Corporation in a report on Friday, July 14th. Six analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $134.50.
In related news, Director Raymond Dwek sold 3,490 shares of the company’s stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $131.71, for a total transaction of $459,667.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Christopher Causey sold 580 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $134.48, for a total transaction of $77,998.40. Following the sale, the director now directly owns 3,295 shares in the company, valued at approximately $443,111.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,964 shares of company stock worth $3,118,533. Corporate insiders own 7.80% of the company’s stock.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.